Cannabidiol: a Novel Intervention for Cannabis Use Problems?
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be recruited from the community. Stage one aims to identify the Most Effective Dose (MEDmg) of oral cannabidiol for reducing cannabis use over four treatment weeks. Stage two will determine whether the MED identified in stage 1 can offer an effective treatment for cannabis dependence.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
16 Years to 60 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Aged between 16 and 60 years old.
Meet DSM-5 criteria for moderate cannabis use disorder (≥4 DSM-5 criteria)
Express desire to quit using cannabis within the next four weeks,
Have ≥1 previous failed quit attempt.
Smoke tobacco with cannabis,
Test positive for recent cannabis use according to urine analysis,
Vital signs within healthy limits and have capacity to give consent
Not willing to use effective contraception from when consent is taken to 6 weeks after treatment has stopped
Positive pregnancy test or breastfeeding
Allergies to the Investigational Medicinal Product (IMP) or placebo and its excipients
>twice/month use of other illicit drugs
Outside normal Body Mass Index (BMI)
A physical health problem deemed clinically significant
The use of current prescribed psychotropic drugs
Current or prior self-reported diagnosis of a psychotic disorder